Soleno Therapeutics Enters Material Agreement, Creates Financial Obligation

Ticker: SLNO · Form: 8-K · Filed: 2025-11-12T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, financial-obligation

TL;DR

SOLENO just signed a big deal and owes money, filing shows.

AI Summary

On November 10, 2025, Soleno Therapeutics, Inc. entered into a material definitive agreement, likely related to financing or a significant business transaction. This event also created a direct financial obligation for the company. The filing indicates other events and includes financial statements and exhibits.

Why It Matters

This filing signals a significant development for Soleno Therapeutics, potentially impacting its financial standing and future operations due to the new definitive agreement and financial obligation.

Risk Assessment

Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce new risks related to the terms of the agreement and the company's ability to meet its obligations.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Soleno Therapeutics, Inc. on November 10, 2025?

The filing indicates the entry into a material definitive agreement but does not specify its nature in the provided text.

What type of direct financial obligation was created for Soleno Therapeutics, Inc.?

The filing states that a direct financial obligation was created, but the specific details of this obligation are not provided in the excerpt.

What are the principal executive offices of Soleno Therapeutics, Inc.?

The principal executive offices of Soleno Therapeutics, Inc. are located at 100 Marine Parkway, Suite 400, Redwood City, CA 94065.

When was Soleno Therapeutics, Inc. incorporated?

Soleno Therapeutics, Inc. was incorporated in Delaware.

What is the SEC file number for Soleno Therapeutics, Inc.?

The SEC file number for Soleno Therapeutics, Inc. is 001-36593.

From the Filing

0001193125-25-275674.txt : 20251112 0001193125-25-275674.hdr.sgml : 20251112 20251112060953 ACCESSION NUMBER: 0001193125-25-275674 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20251110 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251112 DATE AS OF CHANGE: 20251112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 251468310 BUSINESS ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 8-K 1 d63564d8k.htm 8-K 8-K SOLENO THERAPEUTICS INC false 0001484565 0001484565 2025-11-10 2025-11-10     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 10, 2025     SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-36593   77-0523891 (State or other jurisdiction of incorporation)   (Commission File No.)   (IRS Employer Identification Number) 100 Marine Parkway , Suite 400 Redwood City , CA 94065 (Address of principal executive offices) (650) 213-8444 (Registrant’s telephone number, including area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbol   Name of each exchange on which registered Common Stock, $0.001 par value   SLNO   NASDAQ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01. Entry into a Material Definitive Agreement. Accelerated Share Repurchase On November 10, 2025, Soleno Therapeutics, Inc. (the “ Company ”) entered into a confirmation and a supplemental confirmation (together, the “ ASR Agreement ”) of an accelerated share repurchase transaction with Jefferies LLC (the “ Dealer ”). Under the ASR Agreement, the Company shall repurchase an aggregate of $100.0 million of the Company’s common stock, $0.001

View on Read The Filing